核酸适体药物偶联物——肿瘤精准治疗新风向  

Aptamer-drug conjugates(ApDCs):new trend for cancer precision therapy

作　　者：韩永琪 韩达 閤谦[1] 姬丁坤 谭蔚泓 HAN Yongqi;HAN Da;XIA Qian;JI Dingkun;TAN Weihong(Institute of Molecular Medicine,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China;College of Chemistry and Materials Science,Shanghai Normal University,Shanghai 200234,China)

机构地区：[1]上海交通大学医学院附属仁济医院分子医学研究院,上海200127 [2]上海师范大学化学与材料科学学院,上海200234

出　　处：《上海交通大学学报（医学版）》2022年第9期1176-1181,共6页Journal of Shanghai Jiao tong University:Medical Science

基　　金：上海市自然科学基金面上项目(22ZR1437800);上海市青年科技英才扬帆计划(20YF1424500)。

摘　　要：癌症严重威胁人类的生命健康,癌症的精准治疗至今仍是亟须解决的重大医学难题。精准分子医学,可从分子水平上诊断和治疗肿瘤,为肿瘤诊疗提供新的策略。作为优异的靶向识别分子和药物递送载体,核酸适体及核酸适体偶联物为肿瘤的精准治疗提供了重要的分子工具,已成为肿瘤靶向治疗的前沿新兴领域。该文综述了核酸适体性质及筛选技术、核酸适体药物偶联物的构建及其在临床肿瘤靶向治疗中的应用,并对核酸适体药物在肿瘤精准分子医学中的发展前景进行展望,以期为新型分子靶向药物的开发及其在临床恶性肿瘤治疗中的应用提供新的思路。Cancer is a worldwide medical issue that seriously threatens human health. Precision molecular medicine provides a new strategy for cancer theranostics. As excellent targeting recognition molecules and drug delivery platforms, aptamers and aptamer drug-conjugates(ApDCs) have provided a series of useful molecular tools for cancer precision therapy. In this paper, the properties and the selection techniques of aptamers, the construction of ApDCs and their applications to clinical tumor-targeting therapy are reviewed. Additionally, the challenges and perspective of ApDCs in precision molecular medicine for cancers are presented. This review may provide new horizons for molecular-targeted anti-tumor drugs in the therapy of clinical malignant tumors.

关 键 词：分子医学 核酸适体 抗癌药物 靶向治疗 

分 类 号：R730.5[医药卫生—肿瘤]